Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients by Julio, Montaner SG et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open Access Research
Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir 
Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, 
HIV-Infected Patients
Montaner SG Julio*1, Malte Schutz2, Robert Schwartz3, 
Dushyantha T Jayaweera4, Alfred F Burnside5, Sharon Walmsley6 and 
Michael S Saag7
Address: 1St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada, 2Roche Laboratories, Inc, Nutley, New Jersey, 3Associates in 
Research, Fort Myers, Florida, 4University of Miami School of Medicine, Miami, Florida, 5Burnside Clinic, Columbia, South Carolina, 6Toronto 
Hospital, Toronto, Canada and 7University of Alabama at Birmingham
Email: Montaner SG Julio* - jmontaner@cfenet.ubc.ca
* Corresponding author    
Abstract
Context: Once-daily HIV treatment regimens are being used in clinical practice with the objective
of improving patient acceptance and adherence.
Objective: To evaluate the efficacy and safety of saquinavir-soft-gelatin capsule (SGC)/ritonavir
combination (1600 mg/100 mg) vs efavirenz (600 mg) both once daily and combined with 2
nucleoside analogs twice daily.
Setting: Twenty-six centers in the United States, Canada, and Puerto Rico.
Patients: A total of 171 antiretroviral naive HIV-infected individuals were enrolled in a 48-week,
phase 3, open-label, randomized study.
Main Outcome Measure: Proportion of patients with HIV-RNA levels < 50 copies/mL. The
pharmacokinetic profile of saquinavir-SGC was analyzed in a subset of randomly selected patients.
Results: In the primary intent-to-treat population at week 48, 51% (38/75) and 71% (55/77) of
patients in the saquinavir-SGC/ritonavir and efavirenz groups, respectively, achieved HIV-RNA
suppression < 50 copies/mL (P = .5392, 95% 1-sided confidence interval [CI] = -33.5%). In the on-
treatment (OT) population, 73% (38/52) and 93% (54/58) of patients in the saquinavir-SGC/
ritonavir and efavirenz groups, respectively, had effective viral suppression < 50 copies/mL (P =
.5015, 95% 1-sided CI = -33.4%). Mean CD4+ cell counts increased by 239 and 204 cells/microliters
(mcL), in the saquinavir-SGC/ritonavir and efavirenz groups, respectively, in the OT analysis (P =
.058). Both regimens were reasonably well tolerated, although more gastrointestinal adverse
events were reported with saquinavir-SGC/ritonavir. Pharmacokinetic profiles in 6 patients
showed an observed median Cmin at 24 hours of 429 ng/mL (range, 681750 ng/mL).
Conclusion: Once-daily efavirenz was statistically superior to once-daily saquinavir-SGC/
ritonavir. Gastrointestinal adverse effects were commonly associated with treatment failure in the
saquinavir-SGC/ritonavir arm of the study.
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Introduction
The introduction of highly active antiretroviral therapy
(HAART) has produced dramatic reductions in morbidity
and mortality rates associated with HIV-1 infection in the
United States.[1,2] In clinical trials, HAART has reduced
plasma HIV-1 RNA levels to less than 400 copies/mL in
60% to 90% of patients.[3] Strict adherence to HAART is
necessary to prevent viral replication and the emergence
of drug-resistant viruses, which can compromise the final
therapeutic benefit.[4,5] Treatment regimens with
improved dosing schedules, such as once-daily dosing, are
likely to improve patient acceptance and adherence.[6]
Furthermore, once-daily dosing of HAART may be partic-
ularly beneficial in the implementation of directly
observed therapy (DOT) in prisons, at needle-exchange
sites, and in drug rehabilitation programs.[4]
To date, 6 antiretroviral (ARV) agents, efavirenz, tenofo-
vir, didanosine, lamivudine, coformulated lamivudine/
abacavir, atazanavir and amprenavir boosted with ritona-
vir are approved for once-daily dosing by the US Food and
Drug Administration (FDA). However, in addition to
these drugs, there are several agents such as nevirapine
and other boosted protease inhibitors (PIs) that are being
used once daily in clinical practice based on their half
lives. The availability of a wide choice of once-daily treat-
ment regimens has made it easier for HIV-infected
patients to find an optimal therapy that suits their life-
style. While efavirenz appears to be an ideal once-daily
treatment option due to its potency and convenience with
a low pill burden,[7] adverse events, in particular relating
to the central nervous system, have been reported follow-
ing administration,[8] which may potentially limit its use
in some HIV-infected patients. Additionally, efavirenz
may not be appropriate in some settings because it may
have teratogenic effects.[8]
Ritonavir-boosted PI regimens are widely used in clinical
practice,[9,10] because several boosted PI combinations
have pharmacokinetic profiles that support once-daily
dosing.[11] These include saquinavir/ritonavir,[12]
amprenavir/ritonavir,[13] fosamprenavir/ritonavir,[14]
lopinavir/ritonavir [15] and atazanavir/ritonavir.[16] In
initial studies, positive pharmacokinetic and efficacy data
have been observed with the use of once-daily saquinavir/
ritonavir in PI-naive and experienced individuals.[12,17]
Therefore, to further investigate the saquinavir/ritonavir
boosted PI combination as a potential once-daily treat-
ment regimen, we evaluated the efficacy and safety of
saquinavir-soft-gelatin capsule (SGC)/ritonavir 1600 mg/
100 mg vs efavirenz 600 mg in a prospective, randomized,
multicenter clinical trial. Both treatment regimens were
administered once daily in addition to 2 nucleoside
reverse transcriptase inhibitors (NRTIs) (twice daily) as
part of combination HAART therapy regimens to ARV-
naive, HIV-infected individuals. As part of this clinical
study, the pharmacokinetic profile of saquinavir-SGC was
assessed in a subset of patients.
Materials and methods
Study Design
This was a phase 3, open-label, randomized, multicenter
study conducted at 26 centers in the United States, Can-
ada, and Puerto Rico. Antiretroviral-naive, HIV-infected
adults were randomized to receive either saquinavir-SGC/
ritonavir (1600 mg/100 mg, 9 pills) or efavirenz (600 mg,
3 pills) once daily, both in combination with 2 NRTIs
twice daily. An interim analysis was planned at week 24,
with a follow-up extension to week 48. Once patients
reached 48 weeks, they had the option of continuing in
the study until a common study closure (CSC) date or of
withdrawing at that time. The CSC date was the date on
which the last randomized patient reached 48 weeks of
treatment.
The NRTIs allowed in the study included the following
agents: zidovudine (AZT, Retrovir), lamivudine (3TC, Epi-
vir), 3TC/AZT (Combivir), stavudine (d4T, Zerit), or dida-
nosine (ddI, Videx). The NRTIs were selected by the
investigators following consultation with the study partic-
ipants, with the exception of didanosine, which was
dosed twice daily according to the FDA approval status at
the time this study was conducted. Patients were rand-
omized via stratification of the screening plasma HIV-
RNA value (500075,000 copies/mL vs > 75,000 copies/
mL). Saquinavir-SGC and ritonavir were to be taken at the
same time and with food. The study was designed and
monitored in accordance with Good Clinical Practices.
Prior approval was obtained from institutional review
boards/local ethics committees of the participating cent-
ers and written informed consent was obtained from all
study participants.
Patients
The defined study population consisted of male or female
(nonpregnant, nonnursing) adults (18 years or older),
with HIV-RNA values  5000 copies/mL and CD4+ cell
counts  75 cells/mcL. All patients were ARV-naive (no
more than 2 weeks of previous ARV therapy since HIV
diagnosis). Patients with significant laboratory abnormal-
ities, active hepatitis B or hepatitis C, severe hepatic
impairment, or malignancy requiring chemotherapy or
radiation therapy were excluded from the study.
Study Populations
All efficacy analyses were performed on the primary
intent-to-treat (ITT) and on-treatment (OT) populations.
The primary ITT population included all patients who
received at least 1 dose of study drug after randomization
and had at least 1 efficacy evaluation. The OT populationJournal of the International AIDS Society 2006, 8:36 http://www.jiasociety.org/content/8/2/36
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included those patients in the study who had an observa-
tional value for all efficacy variables and laboratory meas-
urements, at that particular timepoint in the study. The
safety-evaluable population included all randomized
patients who received at least 1 dose of study medication
and had at least 1 postbaseline safety assessment.
Efficacy and Safety Measures
The primary efficacy variable was the proportion of
patients with plasma HIV-RNA values < 50 copies/mL
using the Ultra-Sensitive  assay (Roche Diagnostics), at
weeks 24 and 48. Secondary efficacy analyses included the
change from baseline in CD4+ cell counts. Primary and
secondary variables were assessed at baseline (week 0),
every 4 weeks until week 24, and every 8 weeks until week
48, or at study discontinuation.
Adverse events were graded by intensity, and their rela-
tionship to the study medications was assessed. Fasting
lipid profile was also assessed. Laboratory abnormalities
were graded by severity. Marked laboratory shifts were
defined as a  3 grade shift from baseline (grade 03 or 4
and grade 14).
Pharmacokinetic Subanalysis
A subanalysis was performed to assess the pharmacoki-
netic profile of saquinavir-SGC in a subset of randomly
selected patients. Intensive pharmacokinetic assessments
were performed on patients from 2 preselected study cent-
ers after the completion of 4 weeks of therapy. Following
a standard breakfast, saquinavir-SGC/ritonavir 1600 mg/
100 mg was administered with 2 NRTIs. Samples for anal-
ysis of saquinavir-SGC (7 mL) were taken predosing (hour
0) and at 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose. At
week 4, single trough plasma concentrations of saquina-
vir-SGC were also determined in a larger group of
patients. For patients who took their dose in the morning,
single samples were taken before their next morning dose
(approximately 24 hours later) and for those who took
their dose in the evening, samples were taken at least 12
hours after the previous dose.
Pharmacokinetic Analysis
Saquinavir-SGC plasma concentration was assayed using
a validated SCIEX API liquid chromatography extraction
method with a mass spectrophotometric (LC-MS) detec-
tion system. The method was validated for a range of
53000 ng/mL. For patients who underwent intensive
pharmacokinetic evaluation, the variables assessed were
area under the curve over 24 hours (AUC024 h), maximum
plasma concentration (Cmax) and observed trough plasma
concentration (Cmin). Cmax and Cmin were read directly
from the observed data. The AUC data were obtained by
noncompartmental analysis.
In patients with a single trough plasma sample, Cmin at 24
hours (C24 h) was the pharmacokinetic variable of interest
and saquinavir-SGC C24 h was mathematically extrapo-
lated to reflect 24-hour levels, assuming an elimination
half-life of 56 hours.[18] The equation C1 = C0e(-kel • t)
was used to calculate the saquinavir-SGC C24 h extrapo-
lated levels where: C1 = concentration extrapolated at 24
hours; C0 = observed concentration; kel = the elimination
rate constant for the drug (kel = 0.693/t 1/2); t = differ-
ence in time between C1 and C0; and t 1/2 is defined as the
half-life of the drug.
Descriptive statistics for the pharmacokinetic parameters
of saquinavir-SGC were summarized to compare them
with historical values obtained with the licensed dose of
saquinavir-SGC (1200 mg 3 times daily [TID]).
Statistical Analyses
This study was designed to compare the efficacy of once-
daily dosing of saquinavir-SGC/ritonavir 1600 mg/100
mg vs efavirenz 600 mg at weeks 24 and 48, using the pro-
portion of patients with HIV-RNA values < 50 copies/mL
(response rate). Group differences in the proportion of
patients with HIV-RNA levels < 50 copies/mL were ana-
lyzed using a noninferiority test. The Farrington-Manning
method for testing noninferiority was used to derive P val-
ues and to construct 1-sided 95% confidence intervals
(CI) of the rate difference.[19] If the limit of the 95% 1-
sided CI of the difference rate was greater than -20%, then
noninferiority was concluded. Mean changes from base-
line in CD4+ cell counts were analyzed using an analysis
of variance (ANOVA) model. Safety variables were sum-
marized using descriptive statistics for the entire study
period up to the CSC date. Fisher's exact test was used to
statistically compare the incidence of adverse events in
both treatment groups.
Results
Patients and Study Course
From July 1999 to October 2001, 269 patients were
screened and 171 were randomized to treatment (Figure
1). Six patients withdrew from the primary ITT population
before receiving study medication, giving a total of 165
patients who received study drug. Of these, 13 patients
were excluded because no postrandomization on-drug
efficacy evaluation was available. The resulting primary
ITT population included 75 patients in the saquinavir-
SGC/ritonavir group and 77 patients in the efavirenz
group. Of the primary ITT population, 108 patients com-
pleted all 48 weeks of the study (51 in the saquinavir-
SGC/ritonavir group and 57 in the efavirenz group). At
week 48, the OT population consisted of 110 patients: 52
and 58 patients in the saquinavir-SGC/ritonavir and efa-
virenz arms, respectively. The safety population consisted
of 161 randomized patients: 81 and 80 patients in theJournal of the International AIDS Society 2006, 8:36 http://www.jiasociety.org/content/8/2/36
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saquinavir-SGC/ritonavir and efavirenz group, respec-
tively.
At the CSC date, 51/152 (34%) patients had withdrawn
from the primary ITT population: 28/75 (37%) patients
from the saquinavir-SGC/ritonavir group and 23/77
(30%) patients from the efavirenz group (Figure 1). Of
these, 18 patients withdrew due to failure to return for
reassessment (8 in the saquinavir-SGC/ritonavir arm and
10 in the efavirenz arm), 13 patients refused treatment/
withdrew consent (11 in the saquinavir-SGC/ritonavir
arm and 2 in the efavirenz arm), and 12 withdrew due to
adverse events (8 in the saquinavir-SGC/ritonavir arm and
4 in the efavirenz arm). The demographic and baseline
characteristics of the patients in the saquinavir-SGC/riton-
avir and efavirenz arms were similar, with respect to gen-
der, age, race, baseline HIV-RNA levels and CD4+ counts
(Table 1). The majority (73%) of patients in both arms
was male, 47% were black, and the age range was 1961
years (median, 36 years).
Efficacy
Plasma HIV RNA Response
As shown in Figure 2, in the primary ITT population at
week 24, 63% (47/75) and 83% (64/77) of patients in the
saquinavir-SGC/ritonavir and efavirenz groups, respec-
tively, had HIV-RNA values < 50 copies/mL (P = .5255,
95% 1-sided CI = -32.0%). At the 48-week time-point, the
respective values were 51% (38/75) and 71% (55/77) (P
= .5392, 95% 1-sided CI = -33.5%).
In the OT population, at week 24, 82% (46/56) and 90%
(61/68) of patients had HIV-RNA levels < 50 copies/mL in
the saquinavir-SGC/ritonavir and efavirenz groups,
respectively (P = .0374, 95% 1-sided CI = -19.05%). By
week 48, 73% (38/52) and 93% (54/58) of patients had
HIV-RNA levels < 50 copies/mL, respectively (P = .5015,
95% 1-sided CI = -33.3%).
Changes in CD4+ Cell Counts
At week 24, the mean increase in CD4+ cell counts was
170 cells/mcL in the saquinavir-SGC/ritonavir arm com-
pared with 143 cells/mcL in the efavirenz arm (P = .344;
OT population). At the 48-week study endpoint, this had
increased to 239 cells/mcL and 204 cells/mcL, in the
saquinavir-SGC/ritonavir and efavirenz groups, respec-
tively (P = .058; OT population).
Study design and completion status Figure 1
Study design and completion status. ITT = intent to treat
Efavrienz arm, n=85 Saquinavir soft gelatin capsule/ritonavir arm, n=86
*Up to the common study closure date (October 02, 2001±2 weeks).
Randomized
n=171
Withdrew prior
to receiving study drug
n=4
Withdrew prior to
received study drung
n=2
Efficacy evaluation
not available
n=6
Withdrew from study*
(n=23)
Refused treatment n=2
Failure to return n=10
Adverse event n=4
Laboratory toxicity n=3
Insufficient therapeutic response n=2
Other n=2
Efficacy evaluation
not available
n=7
Withdrew from study*
(n=28)
Refused treatment n=11
Failure to return n=8
Adverse event n=8
Laboratory toxicity n=0
Insufficient therapeutic response n=1
Other n=0
Received treatment
as allocated
n=82
Received treatment
as allocated
n=83
Took medication and had
an efficacy evaluation
(Primary ITT population)
n=75
Took medication and had
an efficacy evaluation
(Primary ITT population)
n=77
Completed 48-week study
n=51
Completed 48-week study
n=57Journal of the International AIDS Society 2006, 8:36 http://www.jiasociety.org/content/8/2/36
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Safety
Overall, adverse events were reported by 98% and 94% of
patients in the saquinavir-SGC/ritonavir and efavirenz
groups, respectively. The majority of adverse events were
mild or moderate in intensity. During the entire study
period, 11% (18/161) of patients in the safety population
discontinued treatment due to adverse events. In the
saquinavir-SGC/ritonavir group 15% (12/81) of patients
experienced adverse events that led to withdrawal and 8%
(6/80) of patients withdrew from the efavirenz group due
to adverse events. The most commonly reported adverse
events leading to withdrawal in the saquinavir-SGC/riton-
avir group were gastrointestinal in nature, including nau-
sea and vomiting. In contrast, weight loss, peripheral
neuropathy and abnormal dreams were the reported
adverse events leading to withdrawal in the efavirenz
group.
Adverse events of moderate, severe or life-threatening
intensity that were considered possibly or probably
Table 1: Summary of Patient Characteristics at Baseline (Primary Intent-to-Treat Population)
Characteristic Saquinavir-SGC 1600 mg + ritonavir 100 
mg, Once Daily (n = 75)
Efavirenz 600 mg Once Daily (n = 77)
Male n (%) 53 (71) 58 (75)
Female n (%) 22 (29) 19 (25)
Race n (%)
White 28 (37) 29 (38)
Black 34 (45) 38 (49)
Hispanic 6 (8) 8 (10)
Other 7 (9) 2 (3)
Age (y); mean ± SD(range) 37.2 ± 9.7 (2061) 37.2 ± 9.9 (1961)
Weight (kg); mean ± SD (range) 78.0 ± 16.5 (52126) 75.4 ± 15.0 (44136)
Plasma HIV RNA (log10 copies/mL); mean ± SD 
(range)
4.8 ± 0.6 (3.346.49) 4.7 ± 0.5 (3.515.66)
CD4+ cell count (cells/mcL); mean ± SD (range) 372 ± 190 (751025) 343 ± 180 (80900)
Nucleoside reverse transcriptase inhibitor 
combination therapy; n (%)
3TC-AZT 47 (63) 52 (68)
3TC-d4T 27 (36) 22 (29)
3TC-ddI 0 2 (3)
AZT-ddI 1 (1) 0
d4T-ddI 0 1 (1)
Stratification (HIV RNA); n (%) copies/mL
 500075,000 39 (52) 43 (56)
> 75,000 copies/mL 36 (48) 34 (44)
SGC = soft gelatin capsule; SD = standard deviation; 3TC = lamivudine; AZT = zidovudine; d4T = stavudine; ddI = didanosine.Journal of the International AIDS Society 2006, 8:36 http://www.jiasociety.org/content/8/2/36
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related to study medication occurring in 2% or more of
patients are shown in Table 2 . Overall, 42% (34/81) and
29% (23/80) of patients in the saquinavir-SGC/ritonavir
and efavirenz groups, respectively, reported at least 1
adverse event of moderate, severe, or life-threatening
intensity considered possibly or probably related to study
medication. Among adverse events, the rates of nausea
differed significantly among treatment groups (Table 2).
In total, 15 patients (7 [8.6%] and 8 [10.0%] patients in
the saquinavir-SGC/ritonavir and efavirenz groups,
respectively) reported at least 1 serious adverse event,
none of which were considered to be related to study
medication. One patient in the saquinavir-SGC/ritonavir
group died due to myocardial infarction, which again was
not considered to be related to study medication.
Laboratory Variables
Overall, laboratory grade shifts in hematology and chem-
istry values were similar in both treatment groups. Grade
3/4 total cholesterol laboratory shifts were reported in 3
patients in the saquinavir-SGC/ritonavir group compared
with 7 patients in the efavirenz group. Mean triglyceride
and total cholesterol levels assessed throughout the 48-
week study period are presented in Figure 3. At weeks 24
and 48, mean changes in triglyceride values from baseline
were 29.4 mg/dL and 51.2 mg/dL, respectively, in the
saquinavir-SGC/ritonavir group, compared with 27.0 mg/
dL and 71.4 mg/dL, respectively, in the efavirenz group.
The differences between groups were not statistically sig-
nificant at weeks 24 and 48. Mean changes in total choles-
terol levels were comparable between the 2 treatment
arms throughout the 48-week study period. Mean changes
in high-density lipoprotein cholesterol at weeks 24 and 48
were 7.9 mg/dL and 8.7 mg/dL, respectively, in the
saquinavir-SGC/ritonavir group compared with 9.3 mg/
dL and 12.1 mg/dL, respectively, in the efavirenz group.
Pharmacokinetics
Of 72 patients who were enrolled in the pharmacokinetic
sub-analysis, 6 underwent intensive pharmacokinetic
evaluation. Sixty-five patients had single plasma samples
taken at week 4 and data from 44 patients were suitable
for evaluation of trough concentrations (data from the
remaining 21 could not be extrapolated because the sam-
ples from 11 patients were taken less than 12 hours after
the previous dose and the remaining 10 patients were
noncompliant). Furthermore, of the 6 patients included
in the intensive pharmacokinetic analysis, 1 patient was
noncompliant and, therefore, not included in the single-
trough evaluable cohort of patients. The single-trough
evaluable cohort, therefore, consisted of 49 patients (5
patients with intensive pharmacokinetics and 44 with sin-
gle pharmacokinetic evaluations).
Percentage of patients treated with either saquinavir-soft gelatin capsule/ritonavir or efavirenz both once-daily in combination  with 2 nucleoside reverse transcriptase inhibitors, with undetectable HIV-RNA levels (< 50 copies/mL), as detected by the  Ultra-Sensitive assay Figure 2
Percentage of patients treated with either saquinavir-soft gelatin capsule/ritonavir or efavirenz both once-
daily in combination with 2 nucleoside reverse transcriptase inhibitors, with undetectable HIV-RNA levels (< 
50 copies/mL), as detected by the Ultra-Sensitive assay. ITT = intent to treat; OT = on treatment
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Table 2: Clinical Adverse Events Considered to Be at Least Possibly or Probably Related to Treatment, at Least of Moderate, Severe 
or Life-Threatening Intensity, and Occurring in  2% of Patients in the Safety Population
Adverse Event (ordered by body system) Saquinavir-SGC 1600 mg + ritonavir 100 mg, 
Once Daily (n = 81)
Efavirenz 600 mg Once Daily (n = 80)
n (%) n (%)
Gastrointestinal disorders
Nausea* 18 (22.2) 3 (3.8)
Vomiting NOS 5 (6.2) 0
Diarrhea NOS 4 (4.9) 4 (5.0)
Abdominal pain NOS 2 (2.5) 0
Diarrhea aggravated 2 (2.5) 0
Esophageal reflux 2 (2.5) 0
General disorders
Fatigue 2 (2.5) 4 (5.0)
Dizziness (excluding vertigo) 1 (1.2) 4 (5.0)
Skin and subcutaneous tissue disorders
Dermatitis NOS 1 (1.2) 5 (6.3)
Metabolic and nutritional disorders
Appetite decreased 3 (3.7) 1 (1.3)
Neurologic disorders
Headache NOS 2 (2.5) 2 (2.5)
Insomnia 1 (1.2) 2 (2.5)
Weakness 2 (2.5) 0
Psychiatric disorders
Depression NOS 2 (2.5) 1 (1.3)
Anxiety 1 (1.2) 2 (2.5)
Abnormal dreams 0 2 (2.5)
Vascular disorders
Hypertension NOS 0 2 (2.5)
SGC = soft gelatin capsule; NOS = not otherwise specified.
*P = .0004; Fisher's exact test.Journal of the International AIDS Society 2006, 8:36 http://www.jiasociety.org/content/8/2/36
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Intensive Pharmacokinetic Analysis at 4 Weeks
The intensive pharmacokinetic profile of the 6 unselected
patients evaluated at 9 time points over 24 hours is shown
in Figure 4. The median observed Cmin at 24 hours, Cmax
and AUC024 for these 6 patients were 429 ng/mL (range,
681750 ng/mL), 6435 ng/mL (range, 172013,400 ng/
Mean levels of triglycerides and total cholesterol in the safety population of patients treated with either saquinavir-soft gelatin  capsule/ritonavir or efavirenz both once daily in combination with 2 nucleoside reverse transcriptase inhibitors Figure 3
Mean levels of triglycerides and total cholesterol in the safety population of patients treated with either 
saquinavir-soft gelatin capsule/ritonavir or efavirenz both once daily in combination with 2 nucleoside reverse 
transcriptase inhibitors.
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Intensive pharmacokinetic profile of 6 patients at week 4. EC50 = concentration for 50% maximal effect.
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mL), and 66,920 ng.h/mL (range, 10,542137,563 ng.h/
mL), respectively.
Saquinavir-SGC Trough Levels at Week 4
The median saquinavir-SGC C24 h extrapolated level at
week 4 for all evaluable patients (n = 49) was 376 ng/mL
(range, 2.55709 ng/mL). Eight patients had saquinavir-
SGC C24 h extrapolated levels under the in vivo concentra-
tion for half-maximal effect (EC50) value of 50 ng/mL
(range, 2.545.2 ng/mL).[20] Despite this, these patients
had sustained HIV viral load suppression up to week 24.
There was no significant correlation between saquinavir-
SGC Cmin values and the reduction in plasma HIV RNA
values from baseline to week 48.
Discussion
This 48-week study compared the efficacy and safety of
the once-daily HIV treatment regimens, including
saquinavir-SGC/ritonavir 1600 mg/100 mg, to that of efa-
virenz 600 mg. The primary ITT analysis showed that a
higher proportion of patients in the efavirenz-treated
group achieved HIV-RNA levels < 50 copies/mL compared
with the saquinavir-SGC/ritonavir-treated group. More
patients withdrew from randomized treatment due to gas-
trointestinal disorders in the saquinavir-SGC/ritonavir
arm. The lower virologic response rate observed in the
saquinavir-SGC/ritonavir arm in the ITT population was
predominately due to the high rate of discontinuations,
with 37% of patients withdrawing from the saquinavir/
ritonavir arm, compared with 30% from the efavirenz
arm. These withdrawals were related to gastrointestinal
side effects, and possibly higher pill counts (patients tak-
ing saquinavir-SGC/ritonavir had to take 9 capsules at 1
time compared with 3 efavirenz capsules, together with
the background NRTIs). This study included a high per-
centage of African-American patients and no specific
adherence intervention was provided to overcome the dif-
ference in pill burden in the 2 treatment arms.
A previous comparative randomized trial of the boosted
PI saquinavir-SGC/ritonavir has also shown lower viro-
logic response rates, which have been attributed to differ-
ences in study withdrawal rates as a result of
gastrointestinal toxicities in the saquinavir-SGC study
arms.[21] In the MaxCmin 2 study, which compared
twice-daily saquinavir-SGC/ritonavir with lopinavir/
ritonavir, comparable viral suppression was demonstrated
in the OT analyses; however, the difference in study with-
drawal rates due to gastrointestinal toxicity in the saquina-
vir-SGC/ritonavir arm led to a lower overall response in
the ITT analyses.[21] The gastrointestinal toxicities
encountered in the saquinavir-SGC study arm of MaxC-
min 2 were attributed to the glyceride capmul component
of the SGC formulation of saquinavir.
Saquinavir is available in 2 formulations: the SGC formu-
lation,  Fortovase, and the original hard capsule (HC)
saquinavir mesylate formulation, Invirase. In the present
study, the SGC formulation of saquinavir was used. As a
sole PI (unboosted), the oral bioavailability and effective-
ness of saquinavir with the SGC formulation is higher
than that of the HC formulation. This difference is due to
the glyceride excipient component of the SGC formula-
tion, capmul, which allows saquinavir to dissolve and dis-
perse rapidly upon administration. However, the SGC
formulation is associated with more gastrointestinal
adverse events.[22,23] In a recent study of the saquinavir/
ritonavir boosted regimen, the HC formulation of
saquinavir mesylate demonstrated similar exposure to the
SGC formulation but was better tolerated.[22,24] Conse-
quently, it might be expected that the tolerability issues
encountered in this study could be ameliorated if the HC
saquinavir mesylate formulation of saquinavir was used.
Interestingly, in a further study the boosted saquinavir-
HC/ritonavir 1600 mg/100 mg regimen demonstrated
potent viral suppression (89% of patients had HIV RNA
values < 50 copies/mL) with no patients withdrawing
from the study due to adverse events.[25] Of note, the
saquinavir mesylate is now available as a 500-mg film-
coated tablet, which is similar in size to the saquinavir
mesylate 200 mg HC.
Changes in lipid levels have been associated with the use
of NRTIs and PIs and, consequently, the impact on lipid
levels should be an important consideration when choos-
ing a treatment regimen.[26] With PIs, this risk has been
shown to be greatest with ritonavir, intermediate with
amprenavir and nelfinavir, and lowest with indinavir and
saquinavir.[27,28] The recently approved PI, atazanavir
appears to have little effect on lipid concentra-
tions.[16,27] The lower doses of ritonavir (100200 mg)
that are suitable for boosted saquinavir/ritonavir regi-
mens may result in some increases of fasting triglyceride
and cholesterol levels.[29] The data from this study con-
firm a low lipid profile risk associated with a once-daily
saquinavir-SGC/ritonavir dose of 1600 mg/100 mg. Dur-
ing this study, data evolved regarding the contribution of
NRTIs to hyperlipidemia and a post-hoc analysis was con-
ducted that demonstrated that the predicting factor for
hyperlipidemia in this study appeared to be the use of sta-
vudine as the background NRTI.[30]
Efavirenz once daily is a highly effective and commonly
prescribed part of ARV therapy; however, it may not be
suitable for all patients. Patients taking efavirenz may
experience central nervous system adverse events such as
dizziness, insomnia, poor concentration, and vivid
dreams.[8] With the recent classification of efavirenz as
pregnancy category D caution, it is advised in the treat-
ment of women of child-bearing potential. Also, efavirenzJournal of the International AIDS Society 2006, 8:36 http://www.jiasociety.org/content/8/2/36
Page 10 of 12
(page number not for citation purposes)
use may be a cause for concern in drug users currently tak-
ing methadone because efavirenz-mediated reduction of
methadone blood concentrations has also been
reported.[31,32] No methadone dose adjustments have
been found to be required in patients receiving once-daily
saquinavir/ritonavir 1600 mg/100 mg therapy.[33]
The results of the pharmacokinetic sub-analysis illustrated
that a once-daily regimen including saquinavir-SGC/
ritonavir 1600 mg/100 mg provides a median AUC024 h of
66,920 ng.h/mL. This is significantly higher than might be
anticipated following the unboosted saquinavir SGC regi-
men of 1200 mg 3 times daily, where the AUC08 h is 7249
ng.h/mL.[34] In addition, the median observed Cmin at 24
hours for saquinavir-SGC of 429 ng/mL was substantially
higher than the EC50 value of 50 ng/mL.[20] There is some
evidence that failure on PI therapy can be linked to low
plasma concentrations,[35] but in this study no relation-
ship was found between HIV RNA concentrations and
saquinavir Cmin values.[36] Currently, with antiretroviral
therapy, it is unknown which pharmacokinetic parameter
correlates best with efficacy.[37] While there is some evi-
dence that failure on PI therapy can be linked to low Cmin
plasma concentrations,[20] in this study no relationship
was found between HIV RNA concentrations and saquina-
vir Cmin values.
In conclusion, once-daily efavirenz was statistically supe-
rior to the saquinavir-SGC/ritonavir (1600 mg/100 mg)
once-daily regimen, as part of combination ARV therapy.
Gastrointestinal adverse effects were commonly associ-
ated with (ITT) treatment failure in the saquinavir-SGC/
ritonavir arm of the study, which may be attributed to the
SGC formulation used in this study. Future studies should
evaluate the use of the saquinavir mesylate formulation,
which has demonstrated similar exposure to the ritonavir-
boosted SGC formulation with a better tolerability profile
and by virtue of the 500-mg tablet also provides a lower
pill burden.
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